Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. HOOD
6. QCOM
7. ACN
8. AZN
9. ROIV
10. AAPL

Go back to Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1123.91 -25.45 (2.21%)
Previous Close $1149.36    52 Week High $88.16 
Open $1133.00    52 Week Low $67.88 
Day High $1134.53    P/E 260.16 
Day Low $1113.55    EPS $4.32 
Volume 2,402,813